Government, Policy & Advocacy

29k International AB is a Swedish non-profit tech foundation offering a free mental health app with science-based psychological tools and peer support programs, partnering with institutions including Karolinska Institute and Harvard University. The organization has been involved in clinical research as a digital therapeutic support platform in studies exploring mental health outcomes alongside psychedelic and other novel interventions.

AIM Youth Mental Health is a US non-profit foundation founded in 2014 that funds scientific research and youth-led participatory action research to improve mental health outcomes for young people. The organization funds psilocybin research—including a study on how psilocybin affects genetic aging markers in young adults with stress-related disorders—alongside fellowships for postdoctoral youth mental health innovators.

Advanced Integrative Medical Science (AIMS) Institute is a Seattle-based clinic led by Dr. Sunil Aggarwal offering ketamine-assisted psychotherapy, entheogen-assisted therapy, integrative oncology, and palliative care. The institute is notable for a landmark DEA lawsuit seeking right-to-try psilocybin access for patients with serious illness, placing it at the forefront of psychedelic medicine advocacy and clinical practice in the US.

Alberta Health Services (AHS) is Canada's largest provincial health authority, responsible for delivering healthcare across Alberta and supporting clinical research including in emerging fields like psychedelic-assisted therapy. AHS played a central role in Alberta becoming the first Canadian province to regulate psychedelic-assisted therapy, with its addiction medicine team supporting early access programs and clinical trial infrastructure for psilocybin and MDMA studies.

Psychedelic science education platform founded by British neurobiologist and pharmacologist Andrew R. Gallimore in Tokyo, focused on the neuroscience of DMT, consciousness, and psychedelic pharmacology. Gallimore co-authored a landmark 2016 paper with Rick Strassman proposing target-controlled intravenous DMT infusion for sustained immersive experiences, and publishes the Alien Insect On Drugs Substack alongside immersive educational workshops.

The American Academy of Child and Adolescent Psychiatry (AACAP) is a major US professional medical association representing child and adolescent psychiatrists and publisher of the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP). The organization and its journal have actively engaged with questions around psychedelic-assisted therapy for youth, publishing clinical research and ethical analyses on the potential use of psilocybin and MDMA in adolescent populations.

The American Foundation for Suicide Prevention (AFSP) is the largest non-profit funder of suicide prevention research in the United States, supporting scientific research, survivor outreach, education programs, and advocacy to reduce loss of life from suicide. AFSP has cited emerging psychedelic research—including psilocybin and ketamine studies—among promising avenues for reducing suicidal ideation, reflecting the growing overlap between suicide prevention and psychedelic-assisted therapy.

US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.

The Arizona Biomedical Research Commission (ABRC) is a state government body within the Arizona Department of Health Services that funds biomedical research, having become the first state agency in the US to direct $5 million toward randomized controlled clinical trials of psilocybin whole mushrooms for conditions including PTSD, depression, and addiction. The ABRC oversees the Arizona Psilocybin Research Advisory Council and has since expanded its psychedelic research portfolio to include an additional $5 million for ibogaine clinical trials.

AstraZeneca is a British-Swedish multinational biopharmaceutical company developing medicines across oncology, cardiovascular, respiratory, and neurological areas, with psychiatric products that intersect with psychedelic research contexts. AstraZeneca's antidepressants and psychiatric medications have featured as active comparators in landmark psychedelic clinical trials, including the influential psilocybin vs. escitalopram depression study at Imperial College London.

Australia became the world's first nation to reschedule psilocybin and MDMA as Schedule 8 controlled medicines in February 2023, permitting authorised psychiatrists to prescribe psilocybin for treatment-resistant depression and MDMA for PTSD effective July 2023. The Therapeutic Goods Administration (TGA) leads the regulatory framework for these therapies under a tightly supervised Authorised Prescriber scheme.

Founded in 2020, the Autistic Psychedelic Community (APC) is a Los Angeles-based peer support and co-learning network focused on the intersection of psychedelics and neurodivergent conditions including autism and ADHD, offering psychedelic integration support, panel discussions with researchers, and academic partnerships. Cited in peer-reviewed research, the APC promotes neurodiversity-affirming approaches to psychedelic practice and safe access.

Pharmaceutical company responsible for LUMRYZ REMS implementation in the U.S., including prescriber and pharmacy certification and controlled distribution safeguards.

Beijing Medical Award Foundation (北京医学奖励基金会) is a Beijing-based public charity established in 2002 in Xicheng District, dedicated to enhancing medical standards through professional incentives, grants, and awards recognising biomedical research achievement. The foundation provides funding and recognition supporting clinical and scientific excellence in Chinese medicine, including psychiatry and neuroscience fields.

Berry Consultants is a US statistical consulting firm specializing in Bayesian adaptive clinical trial design, with expertise in platform trials and adaptive dose-finding studies increasingly applied in psychedelic and psychiatric drug development. The firm has engaged with regulatory frameworks for psychedelic medicines, including commenting on FDA guidance for clinical trials involving psilocybin and MDMA.

Biopharmaceutical company responsible for BRIXADI REMS implementation in the U.S., with certified provider and pharmacy requirements and controlled outpatient distribution pathways.

The Canadian Forces Health Services Centre Ottawa is the primary military healthcare facility serving the National Capital Region, providing comprehensive medical, mental health, and occupational health care to Canadian Armed Forces (CAF) personnel and their families. The centre supports CAF members with psychiatric services relevant to trauma and PTSD, areas in which the Canadian military has shown growing interest in ketamine-based and psychedelic-assisted therapies as emerging treatment options.

The Canadian Institutes of Health Research (CIHR) is Canada’s federal health research funding agency, disbursing over $1 billion annually across 13 virtual institutes—including the Institute of Neurosciences, Mental Health and Addiction, which has funded landmark psychedelic medicine trials such as ketamine for bipolar depression at Braxia Scientific and psilocybin-assisted therapy studies at multiple Canadian universities. As the primary source of government funding for psychedelic research in Canada, CIHR plays a pivotal role in building the evidence base for novel psychiatric treatments.

US-based nonprofit institute founded by Brazilian anthropologist Dr. Bia Labate that bridges psychedelic plant medicine traditions and emerging clinical science, producing research and accessible cultural commentary on ayahuasca, psilocybin, and other plant medicines while centering Indigenous reciprocity, racial equity, and social justice. Chacruna hosts annual interdisciplinary conferences since 2018, operates a Racial Equity and Access Committee, and amplifies voices of Indigenous peoples, women, queer communities, and the Global South in psychedelic science and policy.

The Chief Scientist Office (CSO) of the Scottish Government funds NHS and health research across Scotland, and has supported University of Edinburgh evaluability work on ketamine-assisted therapy and the development of the Scottish Psychedelic Research Group to build Scotland’s capacity for psychedelic-assisted therapy studies.

Colorado Division of Professions and Occupations program overseeing facilitator licensing, renewals, complaints, and rule/policy resources for natural medicine services.

Colorado Department of Revenue division responsible for licensing and regulating natural medicine businesses, including healing centers, cultivations, product manufacturers, and testing facilities.

Statutorily created Colorado advisory board providing implementation recommendations for natural medicine regulation, safety standards, licensing architecture, and program oversight priorities.

The Congressionally Directed Medical Research Programs (CDMRP) is a U.S. Department of Defense biomedical research programme that allocates congressional appropriations to fund high-impact, high-risk studies addressing military and veteran health priorities. It has funded clinical trials of psychedelic-assisted treatments for PTSD and traumatic brain injury in Service Members through its Defense Medical Research and Development Program, with over $1.27 billion appropriated for FY2026.

Brazil's National Council for Scientific and Technological Development (CNPq) is the country's primary public funding agency for scientific research, providing grants, scholarships, and R&D support to universities and research institutions nationwide. CNPq ranks among the top global funders of psychedelic science, having supported seminal ayahuasca clinical trials, pharmacological studies, and productivity fellowships for researchers who established Brazil as a world leader in psychedelic psychiatry.

CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is Brazil's federal agency for graduate education improvement, providing scholarships, postdoctoral fellowships, and institutional research grants to universities nationwide. Ranked among the top-six global funders of psychedelic research in a 2023 Scopus analysis, CAPES has financed ayahuasca neuroscience studies, clinical investigations, and postdoctoral programmes that underpin Brazil's internationally recognised psychedelic research ecosystem.

The Czech Health Research Council (AZV ČR) is an organisational component of the Czech Ministry of Health responsible for funding applied health research, distributing over 1 billion CZK annually across approximately 90 supported projects per year. It provided the primary grant for the PSIKET001 trial — a landmark double-blind comparison of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — with a total budget of 12 million CZK.

DoubleBlind is a leading psychedelics-focused biannual print magazine and media company offering investigative journalism, evidence-based reporting, and cultural coverage of the global psychedelic movement, featured in the New York Times, Rolling Stone, and Forbes. The platform also provides online educational courses (on microdosing, mushroom cultivation, and more), expert webinars, and a private member community for psychedelic enthusiasts and professionals worldwide.

Embodied Philosophy is a US-based online contemplative education platform founded in 2015, offering 1,000+ hours of on-demand courses, workshops, and programs spanning Indian philosophy, yoga, consciousness studies, and psychedelic integration to over 100,000 students and seekers worldwide. The Wisdom School serves yoga teachers, therapists, and scholar-practitioners through programs integrating somatic practices, psychedelic experience integration, and Eastern wisdom traditions.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.

EU medicines regulator coordinating scientific and policy dialogue on psychedelic medicinal products, including multi-stakeholder work toward regulatory framework design in the European context.

EU-level drug monitoring authority publishing surveillance and risk intelligence on hallucinogens, including LSD-related trends and associated policy-relevant evidence streams.

The Georgia Department of Veterans Services (GDVS) is a Georgia state agency that assists veterans and their dependents in accessing federal VA benefits, healthcare, educational, and social services. The department supports Georgia veterans' access to emerging mental health treatments including ketamine therapy through VA community care partnerships at the Joseph Maxwell Cleland Atlanta VA Medical Center and affiliated clinics.

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

Canadian federal health regulator administering Special Access Program pathways for restricted drugs, including psychedelic substances under case-by-case clinical access conditions.

The Health Research Board (HRB) is Ireland's primary statutory health research funding agency, which has awarded grants to Trinity College Dublin's Psychedelic Research Group to investigate psychedelics' immune effects in depression and the feasibility of psilocybin for cocaine-use disorder. The HRB also funds the KARMA-DEP(2) ketamine trial for treatment-resistant depression at St Patrick's University Hospital in Dublin, making it a key enabler of Ireland's emerging psychedelic medicine ecosystem.

Non-profit founded in 2009 and headquartered in Barcelona, dedicated to transforming society's relationship with psychoactive plants including ayahuasca, iboga, and cannabis. ICEERS combines scientific research, legal advocacy, harm reduction services, and ethnobotanical education — including conducting the world's first ibogaine clinical trial for opioid dependency.

The Idler is a UK magazine and learning academy founded by Tom Hodgkinson in 1993, championing philosophy, liberal arts, and the good life through online courses — including an exclusive multi-part psychedelics course by Dr. Robin Carhart-Harris of Imperial College London. The Idler Academy's 80+ digital courses make cutting-edge psychedelic science accessible to curious non-specialists worldwide.

Pharmaceutical company responsible for the U.S. SUBLOCADE REMS program, including enrollment, certified healthcare setting controls, and controlled dispensing requirements.

Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.

Instituto Mexicano del Seguro Social (IMSS) is Mexico's largest social security institute, operating the country's most extensive public hospital and clinic network serving over 70 million workers and their families. An IMSS-affiliated facility has participated in clinical research on ketamine for treating depressive symptoms in elderly patients with visual impairment.

Instituto de Salud Carlos III (ISCIII) is Spain's national public health research agency, managing the CIBERSAM network (Centro de Investigación Biomédica en Red de Salud Mental) which co-funds biomedical mental health research across Spanish universities and hospitals. Through CIBERSAM, ISCIII has co-funded preclinical and translational research on psilocybin as an antidepressant and supports researchers contributing to the European psychedelic therapy landscape.

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) is Mexico's federal social security institute for government employees, operating a nationwide network of hospitals and clinics serving millions of public-sector workers and their families. An ISSSTE-affiliated facility has participated in clinical research examining ketamine's effect on depressive symptoms in elderly patients with visual impairment.

The Integrative Psychiatry Institute (IPI), co-founded by Will Van Derveer MD and Keith Kurlander, is a leading US psychedelic-assisted therapy training organization that has trained over 2,200 healthcare providers in 300-hour programs covering ketamine, MDMA, and psilocybin. IPI's psilocybin track was among the first approved by the Oregon Health Authority, and the institute collaborates with the Usona Institute and ASKP³ to develop evidence-based curricula.

Istituto Superiore di Sanità (ISS) is Italy's National Institute of Health, the country's principal technical and scientific public body for biomedical research, public health surveillance, and regulatory advisory functions. The institute has participated in pharmacological research on designer psychoactive substances including methylone, an MDMA analogue, contributing to Italy's evidence base for novel psychoactive substance regulation.

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

Biopharmaceutical company that administers the U.S. XYWAV and XYREM REMS restricted distribution program, including certification, dispensing controls, and program reporting requirements.

Long Alliantie Nederland (Lung Alliance Netherlands) is the Dutch national patient alliance representing people with lung diseases including COPD, asthma, and pulmonary fibrosis; as one of 19 consortium partners in the EU Horizon Europe–funded PsyPal trial (€6.5M), the Alliance contributes patient expertise for the COPD arm investigating psilocybin therapy for psychological distress in palliative care.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

The MIND Foundation is a Berlin-based nonprofit founded in 2016 that advances psychedelic therapy through research, education, and policy advocacy across Europe, supporting clinical trials including the EPIsoDE psilocybin study and the planned DiMension Phase III trial with over 700 patients. It runs the MIND Academy for professional psychedelic training and hosts the biannual INSIGHT conference connecting researchers, clinicians, and the public.

Canadian psychedelic media and events company founded in 2020 and based in Toronto, publishing news, scientific insights, and industry analysis for healthcare, wellness, and finance audiences. Microdose also organizes Microdose X, a global network of local in-person events designed to shift public perception of psychedelic medicine through fireside chats, scientific presentations, and community-building.

Netherlands-based global education, research, and community platform founded in 2017 by Hein Pijnnaken in Brielle, initially as Microdosing.nl and relaunched internationally as Microdosing Institute in 2020, positioned as Europe's first microdosing community with over 6,000 members. Microdosing Institute offers a 6-Week Microdosing Immersion, a Microdosing Facilitator Program, and academic research facilitation, and co-founded the International Microdosing Association alongside James Fadiman.

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

VA medical center in Minneapolis providing healthcare and clinical research for veterans. Part of the Veterans Health Administration network that has committed significant funding to studying MDMA- and psilocybin-assisted therapies for PTSD and treatment-resistant depression in veteran populations.

Public university in St. Joseph, Missouri, home to Dr. Christine Ziemer's pioneering undergraduate courses in psychedelic-assisted psychotherapy and transpersonal psychology covering psilocybin, LSD, MDMA, ketamine, and ayahuasca research and therapeutic applications. Dr. Ziemer founded the Psychedelic Educators Network, serves as executive director of the Psychedelic Society of Kansas City, and supports harm reduction through the Fireside Project and Zendo Project, making Missouri Western a notable hub for Midwestern psychedelic education.

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

NIH center that accelerates the translation of biomedical discoveries into health solutions. NCATS' Clinical and Translational Science Awards (CTSA) program funds the infrastructure at academic medical centers that supports emerging research including psychedelic-assisted therapy trials.

NIH center dedicated to researching complementary and integrative health approaches. NCCIH actively funds psilocybin studies for chronic pain, depression, and alcohol use disorder, and has formally acknowledged psilocybin's therapeutic potential—a significant milestone in the federal recognition of psychedelic medicine.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

The National Center for Research Resources (NCRR) was a National Institutes of Health centre that funded biomedical research infrastructure, clinical and translational science programmes, and shared research resources until its dissolution in 2011, when its programmes were reorganised primarily into the new National Center for Advancing Translational Sciences (NCATS). NCRR infrastructure and clinical research awards supported early NIH-funded investigations into glutamate-modulating medications for major depressive disorder that laid the mechanistic groundwork for understanding ketamine’s rapid antidepressant effects.

The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.

The National Institute for Health and Care Research (NIHR) is the UK’s largest funder of clinical, public health, social care, and translational research, funded by the Department of Health and Social Care with an annual budget of approximately £1.5 billion. NIHR co-funded the KARE trial — the UK’s largest study of ketamine-assisted therapy for alcohol use disorder — and supported the GluEsk trial investigating glutamate biomarkers and esketamine response in treatment-resistant depression.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a US National Institutes of Health institute dedicated to research on alcohol use disorder and its public health impacts, supporting approximately $500 million in research annually. NIAAA has funded studies exploring both ketamine administration for acute alcohol use disorder in the emergency department and psilocybin-assisted therapy to understand the neurobehavioral mechanisms underlying alcohol use disorder treatment.

The US federal biomedical research agency and the world's largest funder of medical research. After decades of absence, NIH began directly funding psychedelic clinical trials in 2021 through NIDA and NIMH, with growing allocations for psilocybin, MDMA, and ketamine research for addiction and mental health conditions.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

The OPEN Foundation is a Dutch non-profit organisation that advances psychedelic research and therapy through scientific conferences, interdisciplinary research, clinician training, and public education. It organises events (including the ICPR conference), runs research and training programmes, and advocates for ethical integration of psychedelics into healthcare in the Netherlands and Europe.

Oregon public health authority operating Oregon Psilocybin Services (OPS), with statutory responsibilities for licensing, regulation, and oversight of psilocybin service delivery under ORS 475A.

State advisory board charged with issuing recommendations to Oregon Health Authority on psilocybin services implementation, professional standards, public health safeguards, and operational controls.

Pancreatic Cancer North America is an IRS-registered 501(c)(3) non-profit dedicated to fighting the world's toughest cancer through research funding, patient support, and awareness initiatives, which has funded a psilocybin-assisted therapy study at Dana-Farber Cancer Institute examining psilocybin's potential to relieve opioid-refractory pain and psychological distress in patients with advanced pancreatic cancer.

PsiloHealth is a psilocybin education, harm reduction, and advocacy organization founded by licensed pharmacist and educator Dr. Sa'ed Al-Olimat, offering a Psilocybin Peer Supporter (PPS) certification, integration workshops, and free educational resources on psilocybin's therapeutic applications. The organization advocates for equitable access to psilocybin-supported care through community education and legislative engagement.

Psilocybin SF offers a comprehensive self-paced online psilocybin course featuring expert faculty from MAPS, Zendo Project, CIIS, and other leading psychedelic organizations, providing accessible education on psilocybin therapy, harm reduction, and integration. Based in San Francisco, the platform serves both individuals and professionals seeking evidence-based psychedelic knowledge.

Psychedelic Coalition for Health (PCH) is a clinician-led psychedelic medicine education and advocacy organization co-founded by psychotherapists Lauren Taus and Nicholas Brüss, offering psychedelic-assisted therapy training, virtual symposia, and scholarship programs for healthcare professionals. PCH trains licensed clinicians in ketamine, MDMA, and IFS-informed approaches while advocating for equitable access to and responsible implementation of psychedelic medicine.

The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.

Breckenridge, Colorado-based psychedelic media and education platform founded in 2016 by Joe Moore and Kyle Buller, reaching over 2.2 million annual learners as the world's largest psychedelic media platform through its podcast, articles, events, and practitioner training programs. Psychedelics Today's Vital Psychedelic Training certification program prepares integration coaches and guides, covering psychedelic-assisted therapy, harm reduction, holotropic breathwork, ethnobotany, and professional development.

Canadian nonprofit research and education organization advancing a systems-based and ecological approach to psychedelics in service of planetary health, developed through interdisciplinary research at the University of Ottawa. Psygaia's framework positions psychedelics as ecological mediators that reweave the human relationship with the living Earth, offering the Microdosing Mindfully course, the Psygaia Circle integration community, guided journey support, and the AFTERGLOW seasonal integration event series across North America.

Regional psychiatric college issuing clinical memoranda and implementation guidance on psychedelic-assisted therapy, including MDMA and psilocybin use in regulated psychiatric contexts.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit founded by the late Dr. Parth Gandhi to advance psychedelic-assisted therapy through education, research, and advocacy in the Intermountain West. SCPTR organizes the annual Intermountain Psychedelic Symposium and supports practitioners, researchers, and policy reform in the region.

Petaluma, California-based transformational learning platform founded in 2010 that has engaged over 3.5 million people across 180 countries, featuring teachers and thought leaders in spirituality, holistic health, psychology, and consciousness expansion. The Shift Network hosts the annual Psychedelic Healing Summit and offers online courses on psilocybin science, therapeutic applications, facilitator selection, and the history and renaissance of psychedelic healing.

Swiss federal authority issuing exceptional licences for otherwise prohibited narcotics, including controlled pathways relevant to psychedelic substances under medical/scientific exceptions.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

U.S. shared-system REMS program for transmucosal immediate-release fentanyl products, maintaining restricted prescriber, pharmacy, and patient enrollment controls.

A nonprofit medical education organization dedicated to advancing psychedelic medicine and psychedelic-assisted psychotherapy. The Board of Medicine certifies clinicians in evidence-based psychedelic treatments, develops best practices for the field, and serves as an educational resource for healthcare providers and the broader community interested in psychedelic therapies.

Australian national regulator implementing schedule controls and authorised-prescriber pathways relevant to MDMA and psilocybin use in tightly regulated psychiatric indications.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

Psilocybin community and harm reduction education hub with a mission to create a world where everyone has safe access to psychedelic medicines. Tripsitters.org covers harm reduction, pharmacology, therapy, ethics, and integration, maintaining a comprehensive directory of psychedelic organizations and practitioners; it is featured as a key resource by the UC Berkeley Center for the Science of Psychedelics.

US federal regulator with statutory authority to require and enforce Risk Evaluation and Mitigation Strategies (REMS) for drug products where additional safety controls are needed.

The research and development arm of the U.S. Department of Veterans Affairs, funding and conducting clinical trials to advance veteran health. Has allocated significant resources to studying MDMA- and psilocybin-assisted therapies for PTSD and other mental health conditions affecting veterans.

atai Life Sciences (operating as atai Therapeutics, Inc. in the US) is a publicly traded clinical-stage biopharmaceutical company founded in 2018 with the largest and most diverse portfolio of psychedelic-derived drug candidates, including DMT, R-MDMA, psilocin, 5-MeO-DMT (BPL-003), and ibogaine for depression, anxiety, and addiction. Following its 2024 merger with Beckley Psytech to form AtaiBeckley, BPL-003 received FDA Breakthrough Therapy designation for treatment-resistant depression with Phase 3 trials anticipated in 2026.

U.S. REMS program for isotretinoin products that enforces pregnancy-prevention controls through prescriber, pharmacy, and patient workflow requirements.